Bosch Francesc, Muntañola Ana, Giné Eva, Carrió Ana, Villamor Neus, Moreno Carolina, Crespo Marta, Montserrat Emili
Department of Hematology and Laboratory of Experimental Hematology, Institute of Hematology and Oncology, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain.
Cytometry B Clin Cytom. 2006 Jul 15;70(4):214-7. doi: 10.1002/cyto.b.20131.
Chronic lymphocytic leukemia (CLL) is a disease with an extremely heterogeneous prognosis. Because of this and because of the lack of a truly effective therapy, treatment of CLL must be adapted to the individual risk of each patient. Over the last quarter of century, prognosis of patients with CLL has been based on clinical features. In the last few years a number of biological prognostic parameters have been identified. Among them, the expression of ZAP-70 in neoplastic B lymphocytes is increasingly being recognized as of paramount importance to predict outcome. Patients with a low percentage (<20%) of ZAP-70 positive neoplastic B lymphocytes have a much better prognosis that those with a higher proportion (>20%) of ZAP-70 positive neoplastic B lymphocytes.
慢性淋巴细胞白血病（CLL）是一种预后极其异质性的疾病。鉴于此以及缺乏真正有效的治疗方法，CLL的治疗必须根据每位患者的个体风险进行调整。在过去的四分之一世纪里，CLL患者的预后一直基于临床特征。在过去几年中，已经确定了一些生物学预后参数。其中，肿瘤性B淋巴细胞中ZAP-70的表达越来越被认为对预测预后至关重要。ZAP-70阳性肿瘤性B淋巴细胞百分比低（<20%）的患者比ZAP-70阳性肿瘤性B淋巴细胞比例高（>20%）的患者预后要好得多。
